|
Karyotype
|
This is a human cell line with the bimodal chromosome number distributions. Both modal populations were hypotetraploid. Cells with higher ploidies occurred at 1%. Nine marker chromosomes were common to all cells: t(4q21q); der(5)t(2;5) (q11.2;q13); i(5p); del(17) (p11.2); del(10) (q22.1) and four others. Of these, del(17) generally had two copies per cell. Seven or more other marker chromosomes including HSR(11) (p15.1) were found in some cells only. Multiple copies of DMs were present in most cells. Consistently there were three normal X chromosomes per cell. N7 had six copies and N14, five copies per cell. Normal N12 was not found.
|
|
Derivation
|
SNU-16 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The line was established from cells taken prior to chemotherapy.
|
|
Clinical Data
|
33 years Asian female SNU-16 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The line was established from cells taken prior to chemotherapy.
|
|
Antigen Expression
|
Blood Type A; Rh + The cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG 72.
|
|
Receptor Expression
|
vasoactive intestinal peptide (VIP), expressed Ref Park JG, et al. Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 50: 2773-2780, 1990. PubMed: 2158397
|
|
Genes Expressed
|
myc +; erb B2 +,Blood Type A; Rh +,The cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG 72.
|
|
Comments
|
SNU-16 cells were positive for VIP receptors but lacked gastrin receptors.
The line was established from cells taken prior to chemotherapy.
No evidence of amplification or rearrangements was noted in the N-myc, L-myc, myb and EGF receptor genes. The c-myc proto-oncogene was apmplified, but expressed c-erb-B-2 RNA that were comparable to other cell lines. There was no expression of the following genes: N-myc, L-myc, c-cis, IGF-2, or gastrin releasing peptide.
The cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG-72. The cells are L-dopa decarboxylase (DDC) positive.
|